Report

The Mexico osteoarthritis therapeutics market was valued at USD 122.29 Million in 2024, driven by the rising prevalence of osteoarthritis and increasing awareness and early detection initiatives across the region. The market is anticipated to grow at a CAGR of 3.90% during the forecast period of 2025-2034, with the values likely to reach USD 179.29 Million by 2034. The market is witnessing growth due to rising aging populations, increased healthcare access, and advanced treatment options like biologics.

Mexico Osteoarthritis Therapeutics Market Overview

A 2025 study published by the University of Texas Medical Branch revealed that osteoarthritis has an estimated prevalence of 20-25% among adults aged 40 and above in region, making it the most common type of arthritis. Osteoarthritis therapeutics involve medications, physical therapy, and surgical interventions to manage joint pain, improve mobility, and slow disease progression. Treatment options include analgesics, nonsteroidal anti-inflammatory drugs, corticosteroids, and disease-modifying therapies. The osteoarthritis therapeutics market in Mexico is growing due to rising obesity rates, an aging population, and increased awareness. The market is anticipated to grow at a CAGR of 3.90% during the forecast period of 2025-2034. Expanding healthcare infrastructure further supports market growth and access to advanced treatments.

Mexico Osteoarthritis Therapeutics Market Growth Drivers

Increasing Prevalence of Obesity to Elevate the Market Growth

The rising prevalence of obesity is significantly affecting the demand for osteoarthritis therapeutics, especially among children and the elderly. According to the INSP and ANM, around 14 million children and adolescents in Mexico are overweight (BMI ? 25) or obese (BMI ? 30). This increasing obesity trend is expected to drive the demand for effective therapeutics, highlighting the growing need for solutions to manage joint pain and improve mobility.

Mexico Osteoarthritis Therapeutics Market Trends

The market is experiencing several notable trends, including the growing adoption of non-surgical treatments and an increase in government efforts to raise awareness about osteoarthritis.

Increasing Adoption of Non-Surgical Treatment Options

There has been a noticeable shift towards non-surgical treatments, including physical therapy and pharmacological interventions such as NSAIDs, corticosteroid injections, and biologics. This trend is driven by the demand for less invasive options and patient preference for non-surgical management, significantly contributing to the market's expansion in Mexico.

Rise in Government Initiatives for Osteoarthritis Awareness to Drive the Mexico Osteoarthritis Therapeutics Market Expansion

Mexico's government is increasingly investing in public health campaigns and initiatives aimed at raising awareness about osteoarthritis. With an emphasis on early diagnosis and preventive care, these efforts are driving higher demand for therapeutics and treatment options, thereby fostering market growth and improving patient access to care.

Mexico Osteoarthritis Therapeutics Market Segmentation

The market report offers a detailed analysis of the market based on the following segments:

Market Breakup by Type

- Hip Osteoarthritis
- Spinal Osteoarthritis
- Knee Osteoarthritis
- Hand Osteoarthritis
- Others

Market Breakup by Drug Class

- Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
- Other Analgesics
- Corticosteroids
- Hyaluronic Acid Injections
- Others

Market Breakup by Dosage Form

- Tablets and Capsules
- Injections
- Creams and Gels
- Others

Market Breakup by Route of Administration

- Oral
- Parenteral
- Topical

Market Breakup by End User

- Hospitals
- Specialty Clinics
- Homecare Settings
- Others

Market Breakup by Distribution Channel

- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others

Mexico Osteoarthritis Therapeutics Market Share

Segmentation Based on Type to Witness Substantial Growth

Based on the type, the market is segmented into hip osteoarthritis, spinal osteoarthritis, knee osteoarthritis, hand osteoarthritis, and others. Knee osteoarthritis is expected to lead the market due to its high prevalence, particularly among the aging population. Increased awareness and advanced treatment options are driving the demand for knee osteoarthritis therapies.

Leading Players in the Mexico Osteoarthritis Therapeutics Market

The key features of the market report comprise clinical trials analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:

Bioventus Inc.

Founded in 2012 and headquartered in Durham, North Carolina, Bioventus is a global leader in orthobiologics. The company expanded into the Mexican osteoarthritis therapeutics market by introducing Durolane, a single-injection hyaluronic acid treatment for mild to moderate knee osteoarthritis. Distributed through Artimedica SA, Durolane supports Bioventus' strategy to enhance joint health solutions and reach patients across Latin America.

GSK plc

GSK plc, a leading biopharmaceutical company established in 2000 and headquartered in London, UK, had strengthened its presence in the osteoarthritis therapeutics market through its participation in a global clinical trial. The company trial evaluated the investigational anti-inflammatory drug GW406381 for the treatment of knee osteoarthritis and included a study site in Mexico. This reflects GSK's strategic efforts at the time to advance osteoarthritis treatment and broaden its reach in the Latin American region.

Sanofi S.A.

Sanofi S.A., established in 1973 and headquartered in Paris, France, is a key player in the osteoarthritis therapeutics market in Mexico. The company has advanced its research in osteoarthritis through the development of SAR113945, an investigational intra-articular suspension designed for single-dose knee injections. This therapy was evaluated in clinical trials to assess pain, inflammation, and functional improvement, utilizing biomarkers. Sanofi's continued engagement reflects its strategic focus on addressing chronic joint conditions, particularly in aging populations prone to osteoarthritis

Novartis AG

Novartis AG, established in 1996 and headquartered in Basel, Switzerland, has long been a prominent player in global healthcare. The company made strides in the osteoarthritis therapeutics market with its clinical trials for LNA043, a drug designed to support cartilage repair.

Other key players in the market include Pfizer Inc., and Bayer AG among others.

Key Questions Answered in the Mexico Osteoarthritis Therapeutics Market Report

- What was the Mexico osteoarthritis therapeutics market value in 2024?
- What is the Mexico osteoarthritis therapeutics market forecast outlook for 2025-2034?
- What are the major factors aiding the Mexico osteoarthritis therapeutics market demand?
- How has the market performed so far, and how is it anticipated to perform in the coming years?
- What are the market's major drivers, opportunities, and restraints?
- What are the major Mexico osteoarthritis therapeutics market trends?
- Which type is expected to dominate the market segment?
- Which drug class is projected to lead the market segment?
- Which dosage form is projected to lead the market segment?
- Which route of administration is anticipated to drive the market segment?
- Which end user is anticipated to drive the market segment?
- Which distribution channel is likely to dominate the market segment?
- Who are the key players involved in the Mexico osteoarthritis therapeutics market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?